Dabrafenib
![]() |
- ₹0
- Product name: Dabrafenib
- CAS: 1195765-45-7
- MF: C23H20F3N5O2S2
- MW: 519.56
- EINECS:689-166-9
- MDL Number:MFCD17215684
- Synonyms:Dabrafenib;Dabrafenib free base(GSK2118436A);GSK2118436A;Dabrafenib (GSK2118436A);Dabrafenib KB-57246;Debrafenib API;BenzenesulfonaMide, N-[3-[5-(2-aMino-4-pyriMidinyl)-2-(1,1-diMethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-;N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|
Properties
Melting point :214-216oC
Boiling point :653.7±65.0 °C(Predicted)
Density :1.443
storage temp. :-20°C
solubility :Soluble in DMSO (up to 30 mg/ml with warming), or in Ethanol (up to 1 mg/ml with warming).
form :White solid.
pka :6.62±0.10(Predicted)
color :Off-white
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChIKey :BFSMGDJOXZAERB-UHFFFAOYSA-N
SMILES :C1(S(NC2=CC=CC(C3=C(C4C=CN=C(N)N=4)SC(C(C)(C)C)=N3)=C2F)(=O)=O)=C(F)C=CC=C1F
Boiling point :653.7±65.0 °C(Predicted)
Density :1.443
storage temp. :-20°C
solubility :Soluble in DMSO (up to 30 mg/ml with warming), or in Ethanol (up to 1 mg/ml with warming).
form :White solid.
pka :6.62±0.10(Predicted)
color :Off-white
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
InChIKey :BFSMGDJOXZAERB-UHFFFAOYSA-N
SMILES :C1(S(NC2=CC=CC(C3=C(C4C=CN=C(N)N=4)SC(C(C)(C)C)=N3)=C2F)(=O)=O)=C(F)C=CC=C1F
Safety Information
Symbol(GHS): |
![]() ![]() |
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Dabrafenib is a selective inhibitor of mutant B-RafV600E (IC50 = 0.8 nM), with 4- and 6-fold reduced potency against wild type B-Raf and c-Raf (IC50s = 3.2 and 5 nM, respectively). It has been investigated in clinical trials in patients with B-RafV600E metastatic melanoma and other solid tumors and is often combined with the MEK inhibitor trametinib to circumvent the development of B-Raf inhibitor resistance.Related product price
- Crizotinib
₹13174.03 - Y27632 (hydrochloride)
₹14800-90886.7 - Dacomitinib (PF299804)
₹5000-14200